AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Resistance to the new generation EGFR-TKI, Osimertinib, can emerge in patients with EGFR-mutated lung cancer. Here, the authors show that AXL, which is activated by osimertinib, can promote the emergence of tolerant lung cancer cell thus conferring resistance to osimertinib and propose the combinati...
Main Authors: | Hirokazu Taniguchi, Tadaaki Yamada, Rong Wang, Keiko Tanimura, Yuta Adachi, Akihiro Nishiyama, Azusa Tanimoto, Shinji Takeuchi, Luiz H. Araujo, Mariana Boroni, Akihiro Yoshimura, Shinsuke Shiotsu, Isao Matsumoto, Satoshi Watanabe, Toshiaki Kikuchi, Satoru Miura, Hiroshi Tanaka, Takeshi Kitazaki, Hiroyuki Yamaguchi, Hiroshi Mukae, Junji Uchino, Hisanori Uehara, Koichi Takayama, Seiji Yano |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2019-01-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-018-08074-0 |
Similar Items
-
Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation
by: Akihiro Yoshimura, et al.
Published: (2019-03-01) -
Prognostic impact of pleural effusion in EGFR‐mutant non‐small cell lung cancer patients without brain metastasis
by: Akihiro Yoshimura, et al.
Published: (2019-03-01) -
Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer
by: Tadaaki Yamada, et al.
Published: (2019-04-01) -
AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer
by: Yuichi Murakami, et al.
Published: (2022-05-01) -
The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations
by: Akihiro Yoshimura, et al.
Published: (2018-12-01)